2013-11-13T08:34:34-06:00 2012-12-31 560747981 DIXON HUGHES GOODMAN LLP 111 ROCKVILLE PIKE 6TH FLOOR ROCKVILLE MD 20850 990 2012-01-01 521986675 FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH INC FOUN 3014025311 9650 ROCKVILLE PIKE NO 3411 BETHESDA MD 20814 MARIA FREIRE PHD 3014025311 2013-10-25 1 ROBIN SKINNER P00742964 2404033700 2012 2016-02-24 21:20:13Z MARIA FREIRE PHD 9650 ROCKVILLE PIKE NO 3411 BETHESDA MD 20814 87446600 0 X HTTP://WWW.FNIH.ORG X 2001 MD THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH WAS ESTABLISHED BY THE UNITED STATES CONGRESS TO SUPPORT THE NIH IN ITS MISSION TO IMPROVE HEALTH, BY FORMING AND FACILITATING PUBLIC-PRIVATE PARTNERSHIPS FOR BIOMEDICAL RESEARCH AND TRAINING. THE FOUNDATION BUILDS PARTNERSHIP FOR DISCOVERY AND INNOVATION TO IMPROVE HEALTH.IN 2012, OUR PORTFOLIO OF WORK EMBRACED A BROAD CONSTELLATION OF PARTNERS FROM MANY INSTITUTES AND CENTERS WITHIN THE NIH, FROM THE NONPROFIT SECTOR AS WELL AS THE PRIVATE SECTOR, INCLUDING PHARMACEUTICAL, TECHNOLOGY, RETAIL, AND FOOD AND BEVERAGE INDUSTRIES AND FROM ORGANIZATIONS AS DIVERSE AS THE NATIONAL FOOTBALL LEAGUE AND GOOGLE. 28 28 54 0 0 0 59765254 58869026 1549687 361074 135308 172757 0 343501 61450249 59746358 25483921 33629180 0 0 5571047 5483858 0 0 141373 19448911 11635220 50503879 50748258 10946370 8998100 98055767 104456171 13622823 12225630 84432944 92230541 X SEE SCHEDULE O, STATEMENT OF ORGANIZATION'S PRIMARY EXEMPT PURPOSE STATEMENT 0 0 45017288 32158554 361074 SEE SCHEDULE O, PROGRAM ONE, RESEARCH PARTNERSHIPS 1325295 1123567 SEE SCHEDULE O, PROGRAM TWO, FELLOWSHIPS AND TRAINING PROGRAMS 35100 8298 SEE SCHEDULE O, PROGRAM THREE, CAPITAL PROJECTS 1246180 338761 SEE SCHEDULE O, MEMORIALS, AWARDS AND EVENTS 1246180 338761 47623863 1 1 0 0 0 1 0 0 1 1 1 1 0 0 1 1 1 0 0 0 1 1 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 31 0 1 54 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 28 28 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD VA NY AL AK AZ AR CA CO CT FL GA HI IL KS KY ME MA MI MS MN NH NJ NM NC ND OH OK OR PA RI SC TN UT WA WV WI X X JULIE TUNE 3014025311 9650 ROCKVILLE PIKE BETHESDA MD 20814 CHARLES A SANDERS MD 2.00 X 0 0 0 PAUL M MONTRONE PHD 1.50 X 0 0 0 JOHN EDWARD PORTER 1.50 X 0 0 0 MRS WILLIAM MCCORMICK BLAIR JR 1.00 X 0 0 0 MRS WILLIAM N CAFRITZ 0.50 X 0 0 0 ANN LURIE 0.50 X 0 0 0 JOSEPH M FECZKO MD 0.50 X 0 0 0 MILES GILBURNE 0.50 X 0 0 0 SHERRY LANSING 0.50 X 0 0 0 MARTIN MURPHY JR MD 0.50 X 0 0 0 STEVEN M PAUL MD 0.50 X 0 0 0 JILLIAN SACKLER DBE 0.50 X 0 0 0 LILY SAFRA 0.50 X 0 0 0 ELLEN V SIGAL PHD 0.50 X 0 0 0 SOLOMON H SNYDER MD 0.50 X 0 0 0 SAMUEL O THIER MD 0.50 X 0 0 0 PATRICK C WALSH MD 0.50 X 0 0 0 ANNE WOJCICKI 0.50 X 0 0 0 PAUL BERG PHD 0.50 X 0 0 0 LUTHER W BRADY MD 0.50 X 0 0 0 FREDA C LEWIS-HALL MD 0.50 X 0 0 0 MARIA FREIRE PHD 40.00 X 62048 0 11248 NINA SOLARZ 0.50 X 0 0 0 JAMES H DONOVAN 0.50 X 0 0 0 PAUL L HERRLING PHD 0.50 X 0 0 0 RONALD L KRALL MD 0.50 X 0 0 0 EDISON T LIU MD PHD 0.50 X 0 0 0 JOEL S MARCUS 0.50 X 0 0 0 STEVEN C MAYER 0.50 X 0 0 0 GARRY A NEIL MD 0.50 X 0 0 0 KATHY BLOOMGARDEN 0.50 X 0 0 0 DAVID WHOLLEY 40.00 X 266107 0 35752 STEPHANIE JAMES 40.00 X 269172 0 25000 ANDREA BARUCHIN 40.00 X 187953 0 23751 JULIE TUNE 40.00 X 173184 0 28070 ANN ASHBY 40.00 X 198758 0 30628 JULIA WOLF-RODDA 40.00 X 176611 0 28413 MICHAEL GOTTLIEB 40.00 X 220833 0 22083 JUDITH SIUCIAK 40.00 X 149220 0 25674 GAIL LEVINE 40.00 X 140804 0 24832 SONIA PEARSON-WHITE 40.00 X 120307 0 16987 KAREN TOUNTAS 40.00 X 143830 0 25135 SCOTT CAMPBELL 40.00 X 241015 0 29057 2349842 0 326630 14 1 1 0 CCS ASSOCIATES PO BOX 9125 MCLEAN VA 22102 CONSULTING 1160271 EPHIR INC PO BOX 253 SWAMPSCOTT MA 01907 RESARCH LAB RELEASE MANAGEMENT 1157812 DIGITAL AURORA PO BOX 648 174 SARGENT LANE MANCHESTER VT 05254 CONSULTING 635914 AMAZON WEB SERVICES LLC PO BOX 84023 SEATTLE WA 98124 WEB SERVICES 340225 TRUVEN HEALTH ANALYTICS INC PO BOX 71716 CHICAGO IL 60694 CONSULTING 262500 18 514000 58355026 58869026 ADMINISTRATIVE FEES 561000 260551 260551 REGISTRATION AND EXHIBIT FEES 541700 100523 100523 361074 140900 140900 27732099 27700242 31857 31857 31857 MISCELLANEOUS REVENUE 541700 343501 343501 343501 59746358 361074 0 516258 21724141 21724141 241750 241750 11663289 11663289 2662974 1717979 927811 17184 1855909 976965 796186 82758 664855 358674 284664 21517 300120 149422 150698 336622 312857 23765 56859 56859 19056 9056 10000 26308 10979 15096 233 712920 637871 75049 395460 184899 210561 1595045 1496357 97096 1592 54414 54414 167788 122030 45758 PROGRAM CONTRACTS 4324306 4324306 CONSULTANTS 4133561 4076393 57168 SERVICE CHARGES 109597 31788 77809 PRINTING AND PHOTOCOPYI 61169 30524 18770 11875 -357885 -445417 81318 6214 50748258 47623863 2983022 141373 55108789 31522531 18080849 11784082 102130 412305 611770 538071 105697 73699 24658302 60663554 98055767 104456171 2561263 1885572 7862751 6386906 3198809 3776556 0 176596 13622823 12225630 X 10078788 10797929 71045848 78113876 3308308 3318736 84432944 92230541 98055767 104456171 X 8998100 74497 -1275000 X X 0 1 X 1 0 X 81264504 71174551 61850631 59279254 58355026 331923966 584653 503112 500000 486000 514000 2587765 81849157 71677663 62350631 59765254 58869026 334511731 127072948 207438783 3698901 806143 173991 134140 140900 4954075 339465806 3069458 0.61110 0.47320 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 2 4725 458738 6664514 1 1 0 1 X 3630634 15153 25996 61840 3609943 3690564 3214 -91 63053 3630634 3736712 9744 23343 79235 3690564 3791493 20898 48619 124298 3736712 3777493 10445 104761 101206 3791493 0.92000 0.08000 0 0 464079 392803 71276 147691 145268 2423 73699 BOND MUTUAL FUNDS 630805 F EQUITY MUTUAL FUNDS 304585 F CORPORATE BONDS 171076 F GOVERNMENT BONDS 59012182 F STOCKS 504783 F REIT 18876 F EXCHANGE TRADED FUNDS 21247 F 60663554 CHARITABLE GIFT ANNUITY 176596 176596 X 58837782 74497 41000 -1024073 -908576 59746358 0 59746358 51040185 41000 250927 291927 50748258 0 50748258 PART IV, LINE 2B: AS OF 12/31/2012, THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH, INC HELD $3,776,556 IN AGENCY FUNDS FOR FUTURE DISTRIBUTIONS TO THE NATIONAL INSTITUTES OF HEALTH (NIH). THESE FUNDS ARE DESIGNATED BY THE FUNDER(S) FOR SPECIFIC PROJECTS AT THE NIH, AND WILL BE DISBURSED AS NEEDED. DESCRIPTION OF INTENDED USE OF ENDOWMENT FUNDS: PART V, LINE 4: THE FOUNDATION'S ENDOWMENTS CONSIST OF INDIVIDUAL DONOR-RESTRICTED ENDOWMENT FUNDS ESTABLISHED FOR A VARIETY OF PURPOSES. (E.G. VARIETY OF RESEARCH AND EDUCATIONAL INITIATIVES AT THE FOUNDATION FOR THE NIH). NET ASSETS ASSOCIATED WITH ENDOWMENT FUNDS ARE CLASSIFIED AND REPORTED BASED ON THE EXISTENCE OR ABSENCE OF DONOR-IMPOSED RESTRICTIONS. DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48: PART X, LINE 2: THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE; ACCORDINGLY, THE ACCOMPANYING FINANCIAL STATEMENTS DO NOT REFLECT A PROVISION OR LIABILITY FOR FEDERAL AND STATE INCOME TAXES. THE FOUNDATION HAS DETERMINED THAT IT DOES NOT HAVE ANY MATERIAL UNRECOGNIZED TAX BENEFITS OR OBLIGATIONS AS OF DECEMBER 31, 2012 AND 2011. FISCAL YEARS ENDING ON OR AFTER DECEMBER 31, 2009 REMAIN SUBJECT TO EXAMINATION BY FEDERAL AND STATE TAX AUTHORIES. PART XI, LINE 2D - OTHER ADJUSTMENTS: IN KIND CONTRIBUTIONS REDUCTION IN FUTURE PLEDGES PART XII, LINE 2D - OTHER ADJUSTMENTS: IN KIND CONTRIBUTIONS 1 EAST ASIA & THE PACIFIC 0 0 GRANTMAKING 4233212 EUROPE 0 0 GRANTMAKING 5879397 SUB-SAHARAN AFRICA 0 0 GRANTMAKING 224049 SOUTH ASIA 0 0 GRANTMAKING 1326631 0 0 0 0 0 0 11663289 0 11663289 EUROPE DEVELOP A GENETIC STRATEGY TO DEPLETE OR INCAPACITATE INSECTS 4813262 WIRE TRANSFER EUROPE NON-HUMAN PRIMATE CORE 50775 WIRE TRANSFER SOUTH ASIA MALNUTRITION AND ENTERIC DISEASES NETWORK 783616 WIRE TRANSFER SOUTH ASIA MALNUTRITION AND ENTERIC DISEASES NETWORK 543015 WIRE TRANSFER EUROPE IMMUNOGENICITY STUDY(CECI) 13333 WIRE TRANSFER EUROPE IDENTIFICATION OF HIGH-QUALITY HITS FOR TUBERCULOSIS 359136 WIRE TRANSFER SUB-SAHARAN AFRICA IDENTIFICATION OF HIGH-QUALITY HITS FOR TUBERCULOSIS 224049 WIRE TRANSFER EAST ASIA AND THE PACIFIC MODIFYING MOSQUITO POPULATION AGE STRUCTURE TO ELIMINATE DENGUE TRANSMISSION 4183075 WIRE TRANSFER EUROPE IDENTIFICATION OF HIGH-QUALITY HITS FOR TUBERCULOSIS 422658 WIRE TRANSFER EUROPE DETECTION OF LONG TERM ADVERSE DRUG REACTIONS IN ELECTRONIC HEALTH CARE DATA 220233 WIRE TRANSFER EAST ASIA AND THE PACIFIC BIOMARKERS OSTEOARTHRITIS 50137 WIRE TRANSFER 11 1 0 0 0 0 0 0 PROCEDURE FOR MONITORING GRANTS OUTSIDE THE U.S.: SCHEDULE F, PART I, LINE 2: PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS SOME DEVELOPING COUNTRY INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. 1 BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501(C)(3) 312096 NON HUMAN PRIMATE NEW ASSAY CALIFORNIA PACIFIC MEDICAL CENTER 475 BRANNAN STREET SUITE 220 SAN FRANCISCO CA 94107 950562680 501(C)(3) 10000 SARCOPENIA DUKE UNIVERSITY 2200 WEST MAIN STREET SUITE 820 ERWIN SQUARE PLAZA DURHAM NC 27705 560532129 501(C)(3) 1143084 PROFICIENCY TESTING CENTRAL/CECI FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVE N SEATTLE WA 98109 237156071 501(C)(3) 872491 VIMC/INNATE AND MUCOSAL IMMUNITY DISCOVERY TEAM JOHNS HOPKINS UNIVERSITY 615 N WOLFE ST W1100 BALTIMORE MD 21205 150595110 501(C)(3) 616862 MAL-ED TRUSTEES OF COLUMBIA UNIVERSITY OF THE CITY OF NEW YORK 630 WEST 168TH STREET NEW YORK NY 10032 135598093 501(C)(3) 135311 MOLECULAR APPROACHES TO ALTER OLFACTORY-DRIVEN BEHAVIORS OF INSECT DISEASE VECTORS UNIVERSITY OF MARYLAND BALTIMORE PO BOX 41428 BALTIMORE MD 21203 311678679 170(C)(1) 10000 SARCOPENIA UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 22904 546001796 170(C)(1) 4570722 MAL-ED VACCINE AND GENE THERAPY INSTITUTE FLORIDA 11350 SW VILLAGE PARKWAY THIRD FLOOR PORT ST LUCIE FL 34987 364631835 170(C)(1) 1015550 VIMC/INNATE AND MUCOSAL IMMUNITY DISCOVERY TEAM COLORADO STATE UNIVERSITY 601 HOWES STREET FORT COLLINS CO 80523 846000545 170(C)(1) 466553 MOLECULAR MOSQUITOCIDES: DEVELOPMENT OF AN INNOVATIVE AND ROBUST, PLATFORM-BASED APPROACH FOR SUSTAINABLE INSECTICIDAL CONTROL OF ANOPHELINE MOSQUITOES NIH-FIC 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) 763361 RESEARCH THE OHIO STATE UNIVERSITY 1960 KENNY RD COLOMBUS OH 43210 316025986 170(C)(1) 466655 HIGH THROUGHPUT DISCOVERY OF CHEMICALS THAT INDUCE 'KIDNEY' FAILURE IN THE MALARIAL VECTOR ANOPHELES GAMBIAE UNIVERSITY OF FLORIDA BOARD OF TRUSTEES PO BOX 115500 GAINESVILLE FL 23611 596002052 170(C)(1) 460005 VOLTAGE-SENSITIVE POTASSIUM CHANNEL AS NEW TARGET FOR MOSQUITOCIDES VESTARON CORPORATION 4717 CAMPUS DRIVE SUITE 1200 KALAMAZOO MI 49008 203831543 444678 DEVELOPMENT OF SYNTHETIC CHEMICAL MIMICS OF SELECTIVELY INSECTICIDAL NATURAL PEPTIDES BRIGHAM AND WOMEN'S HOSPITAL 1620 TREMONT STREET 3RD FLOOR RM BC 3002 BOSTON MA 02120 042312909 501(C)(3) 189418 EVALUATION OF THE EFFECTS OF FCRN MUTATIONS ON ANTIBODY HALF-LIFE. DALLAS COUNTY HEALTH DEPARTMENT 1011 W MAIN PO BOX 199 BUFFALO MO 65622 431268846 170(C)(1) 10159 HEART TRUTH -WOMEN, NUMBERS, HEART, LIFESTYLE DIVAS MPH PO BOX 445 COLLEGE PARK MD 20741 271075779 501(C)(3) 37550 HEART TRUTH HEALTH EDUCATION, ACTION, RESOURCES & TRAINING DONALD DANFORTH PLANT SCIENCE CENTER 975 NORTH WARSON ROAD ST LOUIS MO 63132 311584621 501(C)(3) 296387 REGULATORY DEVELOPMENT FOR HEG-MODIFIED MOSQUITOES HEBREW REHABILITATION CENTER 1200 CENTER STREET BOSTON MA 02131 042104298 501(C)(3) 10000 SARCOPENIA HENRY JACKSON FOUNDATION (USMHRP ) 1401 ROCKVILLE PIKE SUITE 600 ROCKVILLE MD 20852 521317896 501(C)(3) 624479 PROFICIENCY TESTING/MAL-ED NORTHEAST DISTRICT DEPARTMENT OF HEALTH 69 SOUTH MAIN STREET UNIT 4 BROOKLYN CT 06234 060896288 170(C)(1) 115000 THE MODEL OF HEART TRUTH HEALTH CAMPAIGN : FOLLOW THE FIFTY NORTH COUNTRY HEALTH CONSORTIUM INC 262 COTTAGE STREET SUITE 230 LITTLETON NH 03561 020503184 501(C)(3) 42987 HEART TRUTH AWARENESS IN THE NORTH COUNTRY NIH- NCCAM 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) 6008 RESEARCH NIH- CLINICAL CENTER 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) 885057 RESEARCH NIHNCI 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) 1809828 RESEARCH NIHNHLBI 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) 34056 RESEARCH NIHNIAID 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) 4289825 RESEARCH NIHNIDDK 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) 338898 RESEARCH NIHNIMH 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) 558754 RESEARCH NIHNINDS 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) 49900 RESEARCH REFUGEE WOMEN'S ALLIANCE 4008 MARTIN LUTHER KING JR WAY SO SEATTLE WA 98108 911296964 501(C)(3) 49992 REFUGEE WOMEN'S ALLIANCE REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES BOX 951406-1100 KINROSS AVENUE 211 LOS ANGELES CA 90095 956006143 501(C)(3) 15705 HIGH PERFORMANCE STATISTICAL INFERENCE FOR OMOP REGENTS OF THE UNIVERSITY OF MINNESOTA NW 5957 PO BOX 1450 MINNEAPOLIS MN 55485 416007513 170(C)(1) 155800 ANALYSIS OF VRC01 LOCALIZATION IN GUT MUCOSA AND CERVICOVAGINAL SECRETIONS WITH WILD TYPE AND MUTANT VRC01 SAGE BIONETWORKS 1100 FAIRVIEW AVENUE NORTH M1-C108 SEATTLE WA 98109 264489946 170(B)(1)(A)(VI) 259361 BREAST CANCER SUMMIT ST ELIZABETH MEDICAL CENTER INC ONE MEDICAL VILLAGE DRIVE FOUNDATIO DEPARTMENT EDGEWOOD KY 41017 610445850 501(C)(3) 58092 HEART TRUTH-WOMEN TAKE CARE: THE YEAR FOR YOU. TRUSTEES OF BOSTON UNIVERSITY 85 E NEWTON ST M-921 BOSTON MA 02118 042103547 501(C)(3) 456238 ILLUMINATING THE CELLULAR TROPISM OF MEASLES VACCINE VIRUSES IN MACAQUES UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1855 FOLSOM STREET/MCB425- BOX 0897 SAN FRANCISCO CA 94143 946036493 501(C)(3) 100000 OSTEOARTHRITIS UNIVERSITY OF PITTSBURGH 3100 CATHERDRAL OF LEARNING PITTSBURGH PA 15260 250965591 501(C)(3) 28750 SARCOPENIA 35 3 AWARDS 9 210000 PROCEDURE FOR MONITORING GRANTS IN THE U.S.: PART I, LINE 2: SCHEDULE I, PART I, LINE 2: PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS FOR-PROFIT INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. FELLOWS SELECTED FOR FOUNDATION FELLOWSHIPS ARE SELECTED THROUGH NATIONWIDE AND INTERNATIONAL COMPETITIONS. THE CLINICAL RESEARCH TRAINING PROGRAM (CRTP) IS OPEN TO ALL THIRD YEAR STUDENTS ENROLLED IN MEDICAL OR DENTAL SCHOOLS. THE WOMEN'S HEALTH FELLOWSHIP PROGRAMS ARE OPEN TO DOCTORAL-LEVEL CANDIDATES WITHIN FIVE YEARS OF RECEIPT OF THE DOCTORAL DEGREE. APPLICATIONS, CONTAINING TRANSCRIPTS AND ESSAYS ON THEIR RESEARCH GOALS ARE SUBMITTED AND REVIEWED BY PANELS OF NIH SCIENTISTS WHO MAKE RECOMMENDATIONS FOR SELECTION. POTENTIAL FELLOWS ARE OFTEN BROUGHT TO THE CAMPUS FOR INTERVIEWS AND FINAL SELECTION. THE FOUNDATION'S FELLOWSHIPS ARE OPEN TO PROFESSIONALS WORKING AT VARIOUS STAGES OF THEIR RESEARCH CAREERS. APPLICANTS TO THE NEUROSCIENCE FELLOWSHIP, FOR EXAMPLE, ARE YOUNG SCIENTISTS WHO WILL BENEFIT FROM EXPERIENCE OF CLINICAL AND BASIC SCIENCE RESEARCH. THE DIRECTOR'S FELLOWSHIP IN COMPLEMENTARY AND ALTERNATIVE MEDICINE RESEARCH SEEKS A MORE EXPERIENCED SCIENTIST WHO IS WELL-POSITIONED TO BECOME A LEADER IN THE FIELD OF COMPLEMENTARY ALTERNATIVE MEDICINE. X X X X 1 0 0 0 0 0 0 0 0 DAVID WHOLLEY 261607 0 0 0 4500 0 25000 0 10752 0 301859 0 0 0 STEPHANIE JAMES 269172 0 0 0 0 0 25000 0 0 0 294172 0 0 0 ANDREA BARUCHIN 187753 0 0 0 200 0 18795 0 4956 0 211704 0 0 0 JULIE TUNE 172684 0 0 0 500 0 17318 0 10752 0 201254 0 0 0 ANN ASHBY 198038 0 0 0 720 0 19876 0 10752 0 229386 0 0 0 JULIA WOLF-RODDA 176611 0 0 0 0 0 17661 0 10752 0 205024 0 0 0 MICHAEL GOTTLIEB 220833 0 0 0 0 0 22083 0 0 0 242916 0 0 0 JUDITH SIUCIAK 148320 0 0 0 900 0 14922 0 10752 0 174894 0 0 0 GAIL LEVINE 135804 0 0 0 5000 0 14080 0 10752 0 165636 0 0 0 KAREN TOUNTAS 143830 0 0 0 0 0 14383 0 10752 0 168965 0 0 0 SCOTT CAMPBELL 241015 0 0 0 0 0 24101 0 4956 0 270072 0 0 0 PART I, LINE 4A SCOTT CAMPBELL $155,833 STATEMENT OF ORGANIZATION'S PRIMARY EXEMPT PURPOSE STATEMENT FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION: THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH WAS ESTABLISHED BY THE UNITED STATES CONGRESS TO SUPPORT THE NIH IN ITS MISSION TO IMPROVE HEALTH, BY FORMING AND FACILITATING PUBLIC-PRIVATE PARTNERSHIPS FOR BIOMEDICAL RESEARCH AND TRAINING. THE FOUNDATION BUILDS PARTNERSHIP FOR DISCOVERY AND INNOVATION TO IMPROVE HEALTH. IN 2012, OUR PORTFOLIO OF WORK EMBRACED A BROAD CONSTELLATION OF PARTNERS FROM MANY INSTITUTES AND CENTERS WITHIN THE NIH, FROM THE NONPROFIT SECTOR AS WELL AS THE PRIVATE SECTOR, INCLUDING PHARMACEUTICAL, TECHNOLOGY, RETAIL, AND FOOD AND BEVERAGE INDUSTRIES AND FROM ORGANIZATIONS AS DIVERSE AS THE NATIONAL FOOTBALL LEAGUE AND GOOGLE. PROGRAM ONE: RESEARCH PARTNERSHIPS FORM 990, PART III, LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS: IN 2012, FNIH PROGRAMS ENCOMPASSED A BROAD SPECTRUM OF BIOMEDICAL RESEARCH - FROM PRECISE, INNOVATIVE FUNDAMENTAL WORK TO UNDERSTAND DISEASE AND ITS PROGRESSION, TO CLINICAL AND FIELD TRIALS TO EVALUATE POTENTIAL NEW THERAPEUTIC INTERVENTIONS, TO LARGE-SCALE METHODS TO MONITOR THE EFFECTS OF EXISTING MEDICINES. THROUGH FNIH, PRIVATE-SECTOR ORGANIZATIONS WITH AN INTEREST IN A DISEASE OR A NEW TECHNOLOGY CAN TEAM UP WITH THE NIH TO ACCELERATE THE PATHWAY FROM COLLABORATION TO INNOVATION. SPORTS AND HEALTH RESEARCH PROGRAM WITH A $30 MILLION DONATION, THE NATIONAL FOOTBALL LEAGUE BECAME THE FOUNDING PARTNER OF THE FNIH'S NEW SPORTS AND HEALTH RESEARCH PROGRAM. WHILE SPECIFIC INITIATIVES HAVE YET TO BE FINALIZED, POTENTIAL AREAS OF RESEARCH INCLUDE BRAIN INJURY, SUDDEN CARDIAC DEATH, HEAT AND HYDRATION-RELATED ILLNESS, JOINT DISEASE, HEALTH EFFECTS OF PERFORMANCE-ENHANCING SUBSTANCES AND CHRONIC PAIN. TRAUMATIC BRAIN INJURY (TBI) IS AN IMPORTANT AREA OF INTEREST FOR PROFESSIONAL FOOTBALL AND OTHER CONTACT SPORTS, AND RESEARCH TO BETTER UNDERSTAND WAYS TO RECOGNIZE AND PREVENT BRAIN INJURY IS A MAJOR FOCUS OF DISCUSSIONS WITHIN THIS NEW PROGRAM. THE IMPACT OF RESEARCH ON BRAIN INJURY WILL EXTEND FAR BEYOND THE NFL, AS TBI IS THE SIGNATURE WOUND OF SOLDIERS FIGHTING IN IRAQ AND AFGHANISTAN AND EACH YEAR, ACROSS AMERICA, AN ESTIMATED 1.7 MILLION PEOPLE SUFFER A BRAIN INJURY DUE TO TRAUMA. THE SPORTS AND HEALTH RESEARCH PROGRAM AIMS TO ATTRACT FUNDING FROM OTHER DONORS, INCLUDING ADDITIONAL SPORTS ORGANIZATIONS. THE FOUNDING GRANT REPRESENTS THE NFL'S SINGLE LARGEST DONATION TO ANY ORGANIZATION IN THE LEAGUE'S 92 YEARS. BIOMARKERS CONSORTIUM A WIDE-RANGING INITIATIVE TO ADVANCE PERSONALIZED MEDICINE, THE BIOMARKERS CONSORTIUM WORKS TO IDENTIFY MEASURABLE INDICATORS OF BIOLOGICAL AND PATHOLOGICAL PROCESSES TO PREDICT, PREVENT AND TREAT DISEASE. AMONG THE PROJECTS UNDERWAY ARE: I-SPY 2 WOMEN NEWLY DIAGNOSED WITH AGGRESSIVE BREAST CANCER SHOULD HAVE MORE RAPID ACCESS TO PROMISING THERAPIES THANKS TO NEW FOOD AND DRUG ADMINISTRATION (FDA) DRAFT GUIDELINES (OR GUIDANCE) BASED ON THE FNIH I-SPY 2 STUDY. I-SPY 2, A PROJECT OF THE BIOMARKERS CONSORTIUM, IS PIONEERING A NOVEL PROTOCOL TO TEST AND GAIN APPROVAL FOR NEW DRUGS, A PROCESS THAT IS NOTORIOUSLY SLOW AND EXPENSIVE. CURRENTLY, IT CAN TAKE MORE THAN A DECADE TO BRING A NEW CANCER DRUG TO MARKET AT A COST OF MORE THAN $1 BILLION-TIME MANY BREAST CANCER PATIENTS SIMPLY DO NOT HAVE. THE TRIAL'S APPROACH IS GROUNDBREAKING IN TWO WAYS: FIRST, IT IS SCREENING VARIOUS POTENTIAL NEW DRUGS WITHIN THE SAME STUDY; AS THESE CANDIDATE DRUGS ARE MOVED OUT - EITHER FOR NEXT-STAGE TESTING OR BECAUSE THEY FAIL - NEW ONES ARE INTRODUCED. SECOND, INSTEAD OF A ONE-SIZE-FITS-ALL TRIAL, CANDIDATE DRUGS ARE ASSIGNED TO PATIENTS BASED ON THE SPECIFIC CHARACTERISTICS OF THEIR TUMOR. THE DRAFT FDA GUIDANCE ON THE SUBJECT SUGGESTS THAT ONCE THESE NEW DRUGS HAVE SHOWN CLINICAL BENEFIT IN THE I-SPY 2 MODEL, THEY SHOULD BE ELIGIBLE FOR ACCELERATED REGULATORY APPROVAL FOLLOWING A CONFIRMATORY TRIAL. THE I-SPY MODEL CUTS IN HALF THE TIME IT NORMALLY WOULD TAKE TO BRING A DRUG TO MARKET AND CAN DRAMATICALLY LOWER THE COSTS. CONSENSUS DEFINITION OF CLINICALLY IMPORTANT SARCOPENIA THIS BIOMARKERS PROJECT TEAM HAS COMPLETED ITS WORK IN ADVANCING THE FIRST EVIDENCE-BASED DEFINITION OF SARCOPENIA (MUSCLE WEAKNESS), A CONDITION THAT RESULTS IN SERIOUS CONSEQUENCES SUCH AS DISABILITY AND INCREASED MORTALITY. IN THE FIRST PHASE OF THE PROJECT, SIX PRINCIPAL INVESTIGATORS ANALYZED POOLED DATA FROM CLINICAL TRIALS AND LARGE OBSERVATIONAL STUDIES, SUCH AS THE HEALTH ABC AND FRAMINGHAM STUDIES. THEIR FINDINGS, REPORTED AT A FOUR-DAY SARCOPENIA CONSENSUS SUMMIT IN MAY, ARE BEING READIED FOR PUBLICATION. THE NEW DEFINITION WILL ASSIST RESEARCHERS, CLINICIANS AND REGULATORS IN DIAGNOSING SARCOPENIA AND THE CONSENSUS-BUILDING PROCESS WILL SERVE AS A MODEL FOR ARTICULATING OTHER EVIDENCE-BASED DEFINITIONS OF GERIATRIC HEALTH PROBLEMS. ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE 2 NOW IN ITS EIGHTH YEAR, THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI) IS THE LARGEST PUBLIC-PRIVATE BRAIN RESEARCH PARTNERSHIP TO DATE, WITH 28 PRIVATE PARTNERS COORDINATED BY THE FNIH. IT REMAINS THE GOLD STANDARD FOR HOW SUCH PARTNERSHIPS CAN ADVANCE BIOMEDICAL RESEARCH. ADNI DATA, COLLECTED ON THE STUDY'S 1,500 PARTICIPANTS, IS PLACED IN THE SCIENTIFIC PUBLIC DOMAIN TO ENCOURAGE ITS USE BY THE BROADEST RANGE OF INVESTIGATORS POSSIBLE. THE ACCOMPLISHMENTS FROM THIS PROGRAM CONTINUE TO INFORM DEVELOPMENT OF NEW THERAPIES AS WELL AS INFLUENCE ADDITIONAL STUDIES. UNDER THE ORGANIZATION OF THE ALZHEIMER'S ASSOCIATION'S WORLD-WIDE ADNI, SIMILAR WORK IS BEING CARRIED OUT IN ARGENTINA, CHINA, EUROPE, JAPAN, AUSTRALIA, TAIWAN AND SOUTH KOREA. BUILDING ON THE SUCCESS OF THE PROGRAM, ADNI HAS GARNERED ADDITIONAL SUPPORT FROM THE BRIN WOJCICKI FOUNDATION AND THE ALZHEIMER'S ASSOCIATION TO CONDUCT WHOLE GENOME SEQUENCING ON 818 STUDY PARTICIPANTS. THIS EFFORT WILL EXPONENTIALLY INCREASE THE AMOUNT OF GENETIC DATA AVAILABLE TO INVESTIGATORS, LIKELY HIGHLIGHTING A WEALTH OF NEW TARGETS FOR RISK ASSESSMENT, INSIGHTS AND THERAPIES. COMPLEMENTARY TO THE SCOPE OF ADNI, THE PROGRAM'S INVESTIGATORS HAVE RECEIVED SUPPORT FROM THE DEPARTMENT OF DEFENSE TO FOLLOW 300 VIETNAM VETERANS, AGED BETWEEN 60 AND 90 YEARS OLD, TO STUDY WHETHER TRAUMATIC BRAIN INJURY AND/OR POST-TRAUMATIC STRESS DISORDER - BOTH COMMON BATTLEFIELD INJURIES - INCREASE THE RISK OF ALZHEIMER'S DISEASE LATER IN LIFE. SPIROMICS ALTHOUGH IT IS THE THIRD-LEADING CAUSE OF DEATH IN THE UNITED STATES, AFFECTING AS MANY AS 24 MILLION PEOPLE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IS STILL POORLY UNDERSTOOD AND TREATMENT OPTIONS ARE LIMITED. SPRIROMICS, OR SUBPOPULATIONS AND INTERMEDIATE OUTCOME MEASURES IN COPD STUDY, IS AN OBSERVATIONAL STUDY WITH TWO MAIN GOALS. THE FIRST IS TO IDENTIFY SUBPOPULATIONS OF COPD PATIENTS THAT SHARE COMMON CHARACTERISTICS. THE SECOND IS TO IDENTIFY BIOMARKERS THAT WILL ENABLE BETTER TRACKING OF THE DISEASE'S PROGRESSION. TOGETHER, THESE EFFORTS SHOULD IMPROVE THE ABILITY OF CLINICAL TRIALS TO DETERMINE WHETHER PARTICULAR THERAPIES ARE WORKING. SIX UNIVERSITY CLINICAL CENTERS ARE WORKING IN PARTNERSHIP WITH THE NATIONAL HEART, LUNG AND BLOOD INSTITUTE TO FOLLOW 3,000 COPD SUFFERERS. OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP AMERICA'S DRUG-APPROVAL PROCESS HAS SET THE GLOBAL STANDARD FOR RIGOROUS SAFETY AND EFFECTIVENESS REVIEW, BUT EVEN WITH CLINICAL TRIALS AND OTHER SAFEGUARDS, IT IS IMPOSSIBLE TO FULLY UNDERSTAND THE IMPACT OF ANY PARTICULAR MEDICAL INTERVENTION UNTIL IT IS WIDELY USED. ONCE DRUGS ARE ON THE MARKET, RESEARCHERS CONTINUE TO STUDY THEM TO IDENTIFY SAFETY ISSUES AND POTENTIAL UNANTICIPATED BENEFITS. IN 2007, RECOGNIZING THAT THE INCREASED USE OF ELECTRONIC HEALTH RECORDS AND AVAILABILITY OF OTHER LARGE SETS OF HEALTH DATA PROVIDED NEW LEARNING OPPORTUNITIES, CONGRESS DIRECTED THE FOOD AND DRUG ADMINISTRATION (FDA) TO CREATE A NEW DRUG SURVEILLANCE PROGRAM TO MORE AGGRESSIVELY IDENTIFY POTENTIAL SAFETY ISSUES. IN RESPONSE, TOGETHER WITH PHRMA AND THE FDA, FNIH LAUNCHED THE OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP (OMOP). THIS INTERDISCIPLINARY, PUBLIC-PRIVATE RESEARCH GROUP IS ENGAGED IN IDENTIFYING THE MOST RELIABLE METHODS FOR ANALYZING HUGE VOLUMES OF DATA DRAWN FROM HETEROGENEOUS SOURCES TO IDENTIFY DRUG SAFETY ISSUES. OVER THE COURSE OF 2011 AND 2012, RESEARCH YIELDED GREATER CONFIDENCE THAT PARTICULAR METHODS USED WITH SPECIFIC TYPES OF DATA CAN RELIABLY IDENTIFY CORRELATIONS BETWEEN INDIVIDUAL MEDICAL INTERVENTIONS AND SPECIFIC HEALTH OUTCOMES. AS EXPERIMENTS CONTINUE TO PROVIDE GREATER UNDERSTANDING OF HOW HEALTH CARE DATA CAN BE ANALYZED EFFECTIVELY, OMOP WILL CONTINUE TO EVALUATE HOW LARGE-SCALE EMPIRICAL EXPERIMENTS CAN BE REFINED FOR MAXIMUM CLINICAL BENEFIT AND IMPROVED DECISION-MAKING. GLOBAL HEALTH COLLABORATING WITH ORGANIZATIONS AROUND THE WORLD, FNIH FURTHERS THE UNDERSTANDING AND CONTROL OF DISEASES THAT SICKEN AND KILL HUNDREDS OF MILLIONS OF PEOPLE EVERY YEAR. WORKING IN THE U.S. AND INTERNATIONALLY, FNIH-FUNDED INVESTIGATORS ARE MAKING STRIDES AGAINST LIFE-THREATENING DISEASES INCLUDING MALARIA, DENGUE, TUBERCULOSIS, ENTERIC INFECTIONS AND MALNUTRITION. GRAND CHALLENGES IN GLOBAL HEALTH THE GRAND CHALLENGES IN GLOBAL HEALTH (GCGH) IS A PARTNERSHIP WITH THE BILL & MELINDA GATES FOUNDATION THAT FOSTERS INNOVATIVE RESEARCH TO ADDRESS SCIENTIFIC OBSTACLES THAT BLOCK PROGRESS AGAINST DISEASES PROMINENT IN DEVELOPING COUNTRIES. FNIH IS INVOLVED WITH SEVERAL GROUNDBREAKING COMPONENTS OF THE PROGRAM. THE VECTOR-BASED CONTROL OF TRANSMISSION: DISCOVERY RESEARCH (VCTR) PROGRAM IS AN EXTENSION OF GCGH FOCUSED ON DEVELOPMENT OF BIOLOGIC, GENETIC OR CHEMICAL STRATEGIES TO CONTROL MOSQUITO-BORNE DISEASES. IN 2012, TESTING OF A PROMISING DENGUE CONTROL TECHNOLOGY THAT ORIGINATED IN AUSTRALIA WAS EXPANDED TO ADDITIONAL FIELD SITES IN BRAZIL AND VIETNAM. RESEARCHERS ARE WORKING TO INHIBIT THE TRANSMISSION OF DENGUE VIRUS THROUGH A BIOCONTROL METHOD - INFECTING THE AEDES MOSQUITOES THAT SPREAD THE DISEASE WITH A BACTERIUM THAT REDUCES VIRAL REPLICATION IN THE MOSQUITO AND, CONSEQUENTLY, THE AMOUNT OF VIRUS PRESENT IN THE INSECTS' SALIVA TO BE PASSED ON WHEN IT BITES. AUSTRALIAN FIELD TRIALS CONTINUE TO COMPARE THE EFFECTS OF DIFFERENT STRAINS OF WOLBACHIA BACTERIA ON VIRAL DEVELOPMENT WITHIN THE MOSQUITOES AS A MARKER TO PREDICT EFFECTS ON DENGUE TRANSMISSION. INVESTIGATORS IN SEVERAL AFRICAN COUNTRIES JOINED A CONSORTIUM WORKING ON A NEW GENETIC METHOD TO DECREASE THE SPREAD OF MALARIA. THE RESEARCHERS ARE DEVELOPING WAYS OF INSERTING AN ENZYME INTO ANOPHELES MOSQUITOES THAT CARRY THE DISEASE. THE ENZYME WILL BE TARGETED TO INACTIVATE A GENE REQUIRED FOR MOSQUITO REPRODUCTION. BY INHIBITING THEIR CAPACITY TO REPRODUCE, THE SCIENTISTS AIM TO REDUCE MOSQUITO NUMBERS BELOW THE LEVEL NECESSARY TO MAINTAIN MALARIA TRANSMISSION. A COMPLETELY DIFFERENT APPROACH TO INTERRUPTING MALARIA TRANSMISSION BRINGS ACADEMIC AND INDUSTRY RESEARCHERS TOGETHER TO SCREEN AND TEST HUNDREDS OF THOUSANDS OF COMPOUNDS FOR THEIR POTENTIAL EFFECTS ON MOSQUITO HOST-SEEKING BEHAVIOR. SEVERAL OF THE MOST EFFECTIVE COMPOUNDS ARE ALREADY BEING PURSUED FOR FURTHER DEVELOPMENT, WITH THE GOAL OF CREATING BETTER REPELLENTS. ETIOLOGY, RISK FACTORS & INTERACTIONS OF ENTERIC INFECTIONS AND MALNUTRITION AND THE CONSEQUENCES FOR CHILD HEALTH & DEVELOPMENT (MAL-ED) THIS PARTNERSHIP WITH THE BILL & MELINDA GATES FOUNDATION AND THE FOGARTY INTERNATIONAL CENTER AT NIH, IS DESIGNED TO INCREASE UNDERSTANDING OF THE COMPLEX INTERACTIONS AMONG ENTERIC INFECTIONS AND MALNUTRITION AND THEIR ASSOCIATION WITH IMPAIRED GROWTH AND COGNITIVE DEVELOPMENT AND POOR VACCINE EFFICACY IN YOUNG CHILDREN. IN FEBRUARY 2012, ENROLLMENT WAS COMPLETED IN A LARGE BIRTH COHORT STUDY. RESEARCHERS ARE MONITORING NEARLY 2,000 CHILDREN - ACROSS EIGHT FIELD SITES IN RURAL AND URBAN SETTINGS ON THREE CONTINENTS - THROUGH THEIR FIRST TWO YEARS OF LIFE. THEY ARE COLLECTING AND TESTING A VARIETY OF BIOSPECIMENS TO IDENTIFY SPECIFIC RISK FACTORS FOR GROWTH AND DEVELOPMENT SHORTFALLS. EARLY DATA SUGGEST INTRIGUING DIFFERENCES AND SIMILARITIES AMONG THE SITES - VALUABLE INSIGHTS THAT WILL INFORM THE DESIGN OF APPROPRIATE INTERVENTIONS. IDENTIFICATION OF HIGH-QUALITY HITS FOR TUBERCULOSIS (HIT-TB) THIS PARTNERSHIP WITH THE BILL & MELINDA GATES FOUNDATION AND THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), SCREENS CHEMICAL LIBRARIES TO IDENTIFY MOLECULES THAT COULD LEAD TO BETTER DRUGS AGAINST TUBERCULOSIS. HIV/AIDS VACCINE DEVELOPMENT FNIH SERVES AS THE PRIMARY AWARDEE FOR THREE RESEARCH PROJECTS THAT ARE PART OF THE BILL & MELINDA GATES FOUNDATION'S COLLABORATION FOR AIDS VACCINE DISCOVERY (CAVD). ON EACH PROJECT, THE VACCINE RESEARCH CENTER AT NIAID WORKS IN COLLABORATION WITH OTHER INSTITUTIONS TO DEVELOP NEW VACCINES TO PREVENT HIV/AIDS. IN 2012, PARTNERS AT THE VACCINE RESEARCH CENTER MADE SIGNIFICANT PROGRESS IN CHARACTERIZING T AND B CELL VACCINE RESPONSES. A NEW TECHNOLOGY (FLUIDIGM) ALLOWS RAPID AND ECONOMICAL SCREENING OF HUNDREDS OF SINGLE CELLS FOR MANY DIFFERENT MARKERS, FACILITATING A MORE PRECISE UNDERSTANDING OF AN INDIVIDUAL'S IMMUNE STATUS. THIS ADVANCE HOLDS GREAT PROMISE FOR EXPANDING THE ABILITY TO MONITOR IMMUNE RESPONSES TO VACCINATION OR INFECTION. DISCUSSIONS WITH THE FDA HAVE ADVANCED PLANNING FOR A PROOF-OF-CONCEPT CLINICAL TRIAL WITH THE POTENTIAL TO EXPEDITE REGULATORY REVIEW OF SYNTHETICALLY DESIGNED VACCINE INSERTS. THIS THREE-ARMED TRIAL WILL COMPARE WILD-TYPE HIV ENV VACCINE CONSTRUCTS WITH MOSAIC AND CONSENSUS CONSTRUCTS TO DETERMINE RELATIVE SAFETY AND EFFICACY. THIS APPROACH WILL FACILITATE THE DESIGN OF BROADLY PROTECTIVE HIV VACCINES. PROGRAM TWO: FELLOWSHIPS AND TRAINING PROGRAMS FORM 990, PART III, LINE 4B, OTHER PROGRAM SERVICES: WHILE TECHNOLOGY PLAYS AN INCREASINGLY VITAL ROLE IN ADVANCING HUMAN HEALTH, PROGRESS IS IMPOSSIBLE WITHOUT A NEW GENERATION OF CAPABLE AND CURIOUS RESEARCHERS. FNIH PROGRAMS IN VARIOUS FORMATS TARGET A WIDE ARRAY OF TOPICS AND EDUCATION LEVELS, MAKING THE WORLD-CLASS METHODS AND RESOURCES OF THE NIH AVAILABLE TO STUDENTS AND RESEARCHERS ALL OVER THE WORLD. MEDICAL RESEARCH SCHOLARS PROGRAM THE INAUGURAL CLASS OF THE MEDICAL RESEARCH SCHOLARS PROGRAM BEGAN TRAINING ON THE NIH CAMPUS LAST FALL. THE PROGRAM WELCOMED 45 OF THE BEST AND BRIGHTEST YOUNG RESEARCHERS FROM 34 MEDICAL, DENTAL AND VETERINARY SCHOOLS ACROSS THE COUNTRY. DURING THE YEAR-LONG PROGRAM, THE STUDENTS CONDUCT BASIC, TRANSLATIONAL OR CLINICAL RESEARCH IN A FIELD OF THEIR CHOICE, GUIDED BY A MENTOR AND A TUTOR. TO FOSTER THE NEXT GENERATION OF MEDICAL RESEARCHERS AND CLINICIAN-SCIENTISTS COMMITTED TO TRANSLATIONAL RESEARCH AND THE PROMISE IT HOLDS FOR THE CONQUEST OF DISEASE, THE PROGRAM IMMERSES STUDENTS IN THE FULL CONTINUUM OF BIOMEDICAL RESEARCH EARLY IN THEIR CAREER TRAINING. IN ADDITION TO THEIR RESEARCH WORK, STUDENTS COMPLETE AN ACADEMIC CURRICULUM AND INTERACT WITH NIH SCIENTIFIC LEADERS - INSTITUTE DIRECTORS, CLINICAL DIRECTORS AND ESTABLISHED INVESTIGATORS. THE PROGRAM MERGES AND BUILDS ON TWO EARLIER, HIGHLY SUCCESSFUL TRAINING PROGRAMS, THE HOWARD HUGHES MEDICAL INSTITUTE-NIH RESEARCH SCHOLARS PROGRAM AND THE CLINICAL RESEARCH TRAINING PROGRAM. THE GOAL IS TO SUPPORT 70 SCHOLARS EACH YEAR. HUMAN GENOME EXHIBITION EMPLOYING THE WORLD-RENOWNED EXPERTISE OF THE SMITHSONIAN INSTITUTION TO INTERPRET COMPLEX CONCEPTS FOR THE GENERAL PUBLIC, A NEW EXHIBITION WILL TELL THE STORY OF THE DISCOVERY OF THE HUMAN GENOME. AN FNIH PARTNERSHIP WITH THE NATIONAL HUMAN GENOME RESEARCH INSTITUTE AND THE NATIONAL MUSEUM OF NATURAL HISTORY, THE INTERACTIVE EXHIBIT WILL OPEN IN JUNE OF 2013 - THE 10TH ANNIVERSARY OF THE MAPPING OF THE HUMAN GENOME AND THE 60TH ANNIVERSARY OF THE DISCOVERY OF THE DOUBLE-HELIX STRUCTURE OF DNA. ONE OF THE GREAT FEATS OF EXPLORATION IN HISTORY, THE HUMAN GENOME PROJECT UNLOCKED A NEW DIMENSION IN SCIENCE AND HEALTHCARE - YET IT REMAINS LARGELY INSCRUTABLE TO THE GENERAL PUBLIC. ACCOMPANIED BY A DYNAMIC EDUCATION AND OUTREACH PROGRAM, THE HANDS-ON EXHIBIT WILL TRACE THE HISTORY OF THE PROJECT AND REVEAL THE ENORMOUS IMPACT GENOMICS HAS HAD ON INDIVIDUALS, HUMANITY AND THE NATURAL WORLD. THEMES WILL INCLUDE HEALTH AND MEDICINE, ETHICS, BIODIVERSITY, ANCESTRY AND WHAT THE FUTURE MAY HOLD. AFTER ITS RUN OF AT LEAST ONE YEAR AT THE NATURAL HISTORY MUSEUM IN WASHINGTON, D.C., THE EXHIBIT WILL TRAVEL NATIONALLY, BRINGING THE WONDERS OF THIS ACHIEVEMENT TO THOUSANDS AROUND THE U.S. PROGRAM THREE: CAPITAL PROJECTS FORM 990, PART III, LINE 4C, OTHER PROGRAM SERVICES: THE FOUNDATION'S CAPITAL PROJECTS ENHANCE THE RESEARCH ENVIRONMENT AT NIH, SUPPORTING AND PROMOTING THE IMPORTANT DISCOVERIES THAT RESULT FROM NIH'S LEADING-EDGE WORK. THE EDMOND J. SAFRA FAMILY LODGE, FOR EXAMPLE, OPENED IN 2005 TO SERVE AS A COMFORTABLE HOME-AWAY-FROM-HOME FOR FAMILIES THAT COME TO NIH'S CAMPUS IN BETHESDA, MARYLAND TO ACCOMPANY PATIENTS WHO ARE PARTICIPATING IN CLINICAL TRIALS OR RECEIVING TREATMENT AT NIH'S CLINICAL CENTER. SO FAR, THE LODGE HAS HOSTED MORE THAN 40,000 FAMILY MEMBERS AND CAREGIVERS OF ADULT PATIENTS FROM ALL OVER THE WORLD. MEMORIALS, AWARDS AND EVENTS FORM 990, PART III, LINE 4C, OTHER PROGRAM SERVICES: COLLABORATION HAPPENS WHEN PEOPLE CONNECT. THAT IS WHY MANAGING AND ORGANIZING MEETINGS AND EVENTS IS FUNDAMENTAL TO THE WORK OF THE FNIH. FROM LECTURES AND WORKSHOPS TO COLLABORATIVE SUMMITS, TELECONFERENCES AND MEDIA OPPORTUNITIES, THE FNIH FACILITATED MORE THAN 60 EVENTS IN 2012 - SPANNING THE GLOBE AND DOZENS OF FIELDS OF RESEARCH. FORM 990, PART VI, SECTION B, LINE 11 PRIOR TO THE SUBMISSION OF THE FOUNDATION FOR NIH'S FORM 990 TO THE INTERNAL REVENUE SERVICE, EACH VOTING MEMBER OF THE BOARD OF DIRECTORS SHALL BE PROVIDED WITH A COPY OF THE FINAL FORM 990 AS COMPLETED BY THE CHIEF FINANCIAL OFFICER. BOARD DIRECTORS SHALL BE PROVIDED WITH AT LEAST TEN BUSINESS DAYS TO REVIEW THE FORM AND RAISE QUESTIONS, MAKE SUGGESTIONS, AND ADDRESS ANY POTENTIAL PROBLEMS OR CONCERNS WITH THE CHIEF FINANCIAL OFFICER. A SPECIAL MEETING OF THE GOVERNANCE COMMITTEE WILL BE CALLED TO REVIEW THE SUGGESTED CHANGES FROM THE BOARD DIRECTORS AND TO APPROVE THE FINAL VERSION OF THE FORM 990 FOR SUBMISSION. FORM 990, PART VI, SECTION B, LINE 12C THE FOUNDATION REQUIRES DIRECTORS, OFFICERS, VOLUNTEER COMMITTEE MEMBERS, AND STAFF MEMBERS TO DISCLOSE REAL AND APPARENT CONFLICTS OF INTEREST FOR THEMSELVES AND THEIR FAMILY MEMBERS AND TO ANNUALLY SIGN A STATEMENT OF COMPLIANCE. AFTER A CONFLICT OR AN APPARENT CONFLICT OF INTEREST HAS BEEN DISCLOSED, THE BOARD OF DIRECTORS OR THE BOARD COMMITTEE, OR THEIR DESIGNEE, IN THE ABSENCE OF THE INTERESTED PERSON, SHALL DETERMINE IF THE CONFLICT OF INTEREST OR THE APPEARANCE OF A CONFLICT OF INTEREST EXISTS AND IS MATERIAL AND WILL DECIDE HOW IT IS TO BE MANAGED OR ELIMINATED. FORM 990, PART VI, SECTION B, LINE 15 IN 2008, A CONSULTANT WAS HIRED TO REVIEW, ANALYZE AND DEVELOP A PROCESS OF DETERMINING SALARIES FOR ALL EMPLOYEES OF THE ORGANIZATION. ALL EMPLOYEES WERE INTERVIEWED AND POSITION DESCRIPTIONS DEVELOPED OR AMENDED AS NEEDED. USING MARKET DATA, THE CONSULTANT DEVELOPED PAY BANDS FOR ALL POSITIONS. FINAL RECOMMENDATIONS WERE REVIEWED BY THE EXECUTIVE DIRECTOR. THE EXECUTIVE DIRECTOR'S COMPENSATION IS REVIEWED AND DETERMINED BY THE EXECUTIVE COMMITTEE OF THE BOARD USING LOCAL MARKET DATA. FORM 990, PART VI, SECTION C, LINE 19 ALL DOCUMENTS ARE AVAILABLE UPON REQUEST. THE AUDITED FINANCIAL STATEMENTS ARE POSTED TO THE ORGANIZATION'S WEBSITE. CHANGES IN NET ASSETS OR FUND BALANCES: FORM 990, PART XI, LINE 9: REDUCTION IN FUTURE PLEDGES -1,275,000. FORM 990, PART XII, LINE 2C: PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR. FORM 990, PART XI, LINE 9, OTHER CHANGES IN NET ASSETS OR FUND BALANCES: DURING 2012, FNIH WAS NOTIFIED BY TWO DONORS THAT THEY COULD NO LONGER SUPPORT THE PROJECT WHICH THEY ORIGINALLY PROMISED TO SUPPORT OVER MULTIPLE YEARS. FNIH RECORDED $1,275,000 AS A REDUCTION IN FUTURE PLEDGES AS OF 12/31/2012.